Welcome!

News Feed Item

NextSource Biotechnology Announces FDA Short Supply release of the formally known Bristol Myers Squibb (CeeNu®) Brand Oncology product now currently marketed under the NextSource Biotechnology Lomustine (CCNU) label Exclusively in the United States

MIAMI, Jan. 24, 2014 /PRNewswire/ -- NextSource BioTechnology, LLC, (NSB), an emerging Specialty Pharmaceutical Manufacturing and Marketing Company focused on Consolidating, Re-Branding and Launching "Matured & Orphan Drugs," has announced its most recent product Lomustine (CCNU), formerly known as CeeNu® by Bristol-Myers Squibb (BMS), which has officially been removed from the U.S. Food & Drug Administration (FDA) Drug Shortage List.  As a result of this new status, Lomustine (CCNU) is now readily available through NextSource's Nationwide Authorized Distribution supply chain.  Please visit us at: http://www.nextsourcebiotechnology.com/authorized_distributors.aspx

(Logo: http://photos.prnewswire.com/prnh/20140124/FL52230LOGO )

Due to the successful product re-launch and market availability of Lomustine (CCNU), there is no longer a need for continued use of the unregulated compound equivalent product. Pharmacies currently compounding this product are doing so against the FDA Code of Federal Regulations.

Lomustine (CCNU) will continue to be distributed under the current name, while the pending FDA "Brand" name is under review for approval.  Lomustine (CCNU) is the first of many "Matured Drugs" to be launched under the NextSource Biotechnology portfolio. 

"Our launch of LOMUSTINE," said Robert DiCrisci, President, CEO of NextSource Biotechnology, "is an example of the NextSource commitment to work proactively with the FDA in an effort to prevent the discontinuation of existing and future drugs that are vital in the application of a well balanced treatment plan of traditional proven therapies and New therapy options that healthcare providers and patients in the hospital settings require under the new healthcare guidelines."

About Lomustine (CCNU) - INDICATIONS AND USES

Lomustine (CCNU) is an oral chemotherapy medication that is used to treat Primary and Metastatic Brain Cancer.  Lomustine belongs to a class of drugs known as nitrosourea anti-tumor alkylating agent.  Unlike the more common nitrogen mustard alkylating agents, Lomustine (CCNU) crosses the blood-brain barrier quite effectively due to its high lipid solubility and the relative lack of ion-ization at physiological pH and is used in the treatment of both primary and metastatic brain tumors in patients.  It works by bonding with DNA of rapidly dividing cells causing breakage of the DNA strands and eventually, the death of the cancer cell. 

Lomustine (CCNU) has been shown to be useful as a single agent in addition to other treatment modalities, or in an established combination therapy with other approved chemotherapeutic agents in the following:

Brain tumors- Both primary and metastatic, in patients who have already received appropriate surgical and/or radio therapeutic procedures.

Hodgkin's disease- secondary treatment in combination with other approved drugs in patients who relapse while being treated with primary therapy or who fail to respond to primary therapy.

About our Partner: CordenPharma is an expert Contract Manufacturing partner helping leading pharmaceutical and biotechnology companies link their requirements for product success with their patients' healthier lives. CordenPharma has subsequently been the long-term manufacturing partner of the Lomustine product for both NextSource Biotechnology and Bristol Myers Squibb (CeeNu®).

Formed as a pharmaceutical branch of International Chemical Investors Group in 2006, CordenPharma provides specialized technologies that are ideal for the development and manufacturing of oral, sterile, highly potent and antibiotic pharmaceutical Drug Products, their Active Pharmaceutical Ingredients, and associated Global Supply Chain and Packaging Services.

References

1. Lomustine Package Insert:  www.nextsourcebio.com 

2. U.S. Food and Drug Administration (FDA) Current Resolved Drug Shortages Index. Available at: http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050793.htm 

3. Press Release:  http://www.nextsourcebiotechnology.com/news_and_media.aspx 

SOURCE NextSource BioTechnology, LLC

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that IBM has been named “Diamond Sponsor” of SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California.
A look across the tech landscape at the disruptive technologies that are increasing in prominence and speculate as to which will be most impactful for communications – namely, AI and Cloud Computing. In his session at 20th Cloud Expo, Curtis Peterson, VP of Operations at RingCentral, highlighted the current challenges of these transformative technologies and shared strategies for preparing your organization for these changes. This “view from the top” outlined the latest trends and developments i...
When growing capacity and power in the data center, the architectural trade-offs between server scale-up vs. scale-out continue to be debated. Both approaches are valid: scale-out adds multiple, smaller servers running in a distributed computing model, while scale-up adds fewer, more powerful servers that are capable of running larger workloads. It’s worth noting that there are additional, unique advantages that scale-up architectures offer. One big advantage is large memory and compute capacity...
"Loom is applying artificial intelligence and machine learning into the entire log analysis process, from start to finish and at the end you will get a human touch,” explained Sabo Taylor Diab, Vice President, Marketing at Loom Systems, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
In 2014, Amazon announced a new form of compute called Lambda. We didn't know it at the time, but this represented a fundamental shift in what we expect from cloud computing. Now, all of the major cloud computing vendors want to take part in this disruptive technology. In his session at 20th Cloud Expo, Doug Vanderweide, an instructor at Linux Academy, discussed why major players like AWS, Microsoft Azure, IBM Bluemix, and Google Cloud Platform are all trying to sidestep VMs and containers wit...
"We are a monitoring company. We work with Salesforce, BBC, and quite a few other big logos. We basically provide monitoring for them, structure for their cloud services and we fit into the DevOps world" explained David Gildeh, Co-founder and CEO of Outlyer, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
In his session at @ThingsExpo, Eric Lachapelle, CEO of the Professional Evaluation and Certification Board (PECB), provided an overview of various initiatives to certify the security of connected devices and future trends in ensuring public trust of IoT. Eric Lachapelle is the Chief Executive Officer of the Professional Evaluation and Certification Board (PECB), an international certification body. His role is to help companies and individuals to achieve professional, accredited and worldwide re...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
Automation is enabling enterprises to design, deploy, and manage more complex, hybrid cloud environments. Yet the people who manage these environments must be trained in and understanding these environments better than ever before. A new era of analytics and cognitive computing is adding intelligence, but also more complexity, to these cloud environments. How smart is your cloud? How smart should it be? In this power panel at 20th Cloud Expo, moderated by Conference Chair Roger Strukhoff, pane...
@DevOpsSummit at Cloud Expo taking place Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center, Santa Clara, CA, is co-located with the 21st International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is ...
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists examined how DevOps helps to meet the de...
No hype cycles or predictions of zillions of things here. IoT is big. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, Associate Partner at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He discussed the evaluation of communication standards and IoT messaging protocols, data analytics considerations, edge-to-cloud tec...
What's the role of an IT self-service portal when you get to continuous delivery and Infrastructure as Code? This general session showed how to create the continuous delivery culture and eight accelerators for leading the change. Don Demcsak is a DevOps and Cloud Native Modernization Principal for Dell EMC based out of New Jersey. He is a former, long time, Microsoft Most Valuable Professional, specializing in building and architecting Application Delivery Pipelines for hybrid legacy, and cloud ...
Amazon started as an online bookseller 20 years ago. Since then, it has evolved into a technology juggernaut that has disrupted multiple markets and industries and touches many aspects of our lives. It is a relentless technology and business model innovator driving disruption throughout numerous ecosystems. Amazon’s AWS revenues alone are approaching $16B a year making it one of the largest IT companies in the world. With dominant offerings in Cloud, IoT, eCommerce, Big Data, AI, Digital Assista...
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business - from apparel to energy - is being rewritten by software. From planning to development to management to security, CA creates software that fuels transformation for companies in the applic...